On October 26, 2024, the Second Annual Conference of the National Infectious Disease Medical Center's Infectious Disease Specialty Alliance was held in Kunming, Yunnan. During the event, a strategic cooperation agreement was signed between Baheal Pharma and the National Infectious Disease Medical Center (Beijing) and Beijing Ditan Hospital. This partnership aims to address major national needs in infectious disease prevention and treatment, focusing on technology innovation, result transformation, and talent cultivation. Attending the signing ceremony were Jin Ronghua, Director of the National Center for Infectious Diseases (Beijing) and President of Beijing Ditan Hospital; Chen Xiaoyou, Executive Vice President of Beijing Ditan Hospital; Yang Zhiyun, Vice President; Tian Xin, Deputy Secretary; Li Xin, Director of the Science and Technology Department; Song Qing, Director and President of Baiyang Pharmaceutical Group; Wang Biquan, Vice President of Innovative Drugs and Devices; and Zhang Shuying, Strategic Customer Director.

As a leading tertiary hospital specializing in infectious diseases, Beijing Ditan Hospital plays a crucial role in China’s epidemic prevention and control efforts. In 2021, it was officially designated as the National Infectious Disease Medical Center (Beijing) by the National Health Commission. The center plays a leading and exemplary role domestically in specialized fields with international competitiveness and influence in the diagnosis and treatment of complex and critical diseases, training of high-level medical talent, advanced basic medical research and its translation into practice, solving major public health issues, and modern hospital management.

This partnership agreement will leverage the strengths of both parties in medical specialties, talent, technology, and industry resources to pilot a new model of collaboration between hospitals and enterprises for the commercialization of scientific research. The deepened cooperation will focus on technological innovation, research translation, and talent cultivation, aiming to address the current challenges and bottlenecks in basic research and the commercialization of scientific advancements. The goal is to convert original research findings in the field of infectious diseases into practical clinical applications, thereby enhancing China's capabilities in the prevention, treatment, and diagnosis of infectious diseases.

Jin Ronghua, Director of the National Center for Infectious Diseases (Beijing) and President of Beijing Ditan Hospital affiliated with Capital Medical University, stated that the center bears a significant responsibility in China's infectious disease prevention and control. This collaboration represents another crucial step in the partnership between hospitals and enterprises to drive innovation and the commercialization of research outcomes. Jin expressed hope that this cooperation will accelerate the development and translation of innovative achievements in the field of infectious diseases, thereby significantly contributing to the high-quality advancement of infectious disease prevention and control efforts.

This signing also marks an important step for Baheal Pharma Group in the commercialization of innovative outcomes through partnerships with national research institutions. Song Qing, Director and President of Baiyang Pharmaceutical Group, stated that leveraging its extensive industrial resources and robust innovation incubation system, Baheal is pursuing groundbreaking innovation under the guidance of the national science and technology innovation strategy. By partnering with the National Center for Infectious Diseases (Beijing), Baheal aims to advance the translation of scientific research in infectious diseases into practical applications, thereby optimizing medical scenarios and better serving patients and public health.

Baheal Pharma, with its extensive experience as an “industrial investor” in the healthcare sector, is focusing on three key areas: innovative drugs, high-end medical devices, and foundational research platforms. The company collaborates with national entities to uncover first-in-class innovations and breakthrough technologies, leveraging its industry resources to facilitate the commercialization and rapid clinical integration of these innovations. To date, it has established deep partnerships with institutions such as Peking University Health Science Center, Capital Medical University, the Chinese Academy of Medical Sciences, Rehabilitation University, and Xuanwu Hospital. These collaborations aim to identify and develop clinically valuable innovations from the source. Significant progress has already been made in areas such as fully magnetically levitated artificial hearts, medical linear electron accelerators, electromagnetic guided biopsy equipment, innovative nuclear medicine drugs and SPECT/CT, as well as in anti-cancer and bone regeneration drugs.

Moving forward, Baheal intends to harness its role as a catalyst for medical innovation, addressing unmet clinical needs and fostering collaborations to ensure that more original and commercially viable innovations are transformed into real-world applications, ultimately optimizing healthcare delivery.